| Not Yet Recruiting | Resistance Profiling Using Functional Imaging and Next Generation Sequencing in Refractory Gastrointestinal St NCT07109024 | Universität Duisburg-Essen | — |
| Not Yet Recruiting | CEH-EUS for Differentiating GISTs and Leiomyomas: A Multicenter Prospective Self-Controlled Study NCT07106411 | Huazhong University of Science and Technology | — |
| Recruiting | Multicenter Observational Study of Multimodal AI for Upper GI Mesenchymal Tumor Diagnosis NCT07078136 | Huazhong University of Science and Technology | — |
| Recruiting | A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors ( NCT06655246 | Kura Oncology, Inc. | Phase 1 |
| Recruiting | An International Study on Pediatric Patients With Rare Tumors. NCT07072143 | Azienda Ospedaliera di Padova | — |
| Recruiting | A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST) NCT06630234 | Deciphera Pharmaceuticals, LLC | Phase 1 / Phase 2 |
| Unknown | Endoscopic Ultrasound Radiofrequency Ablation for GISTs NCT05453292 | Instituto Ecuatoriano de Enfermedades Digestivas | N/A |
| Recruiting | First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal T NCT05489237 | IDRX, Inc., a wholly owned subsidiary of GSK, LLC | Phase 1 |
| Unknown | Ripretinib Combined With Surgery in Advanced GIST That Have Failed Imatinib Therapy: A Multicenter,Observation NCT05354388 | Sichuan Provincial People's Hospital | — |
| Active Not Recruiting | Oncogenetic Panel and Integrated Clinical Data Registry Study for Wild Type Gastrointestinal Stromal Tumor Pat NCT04821895 | National Health Research Institutes, Taiwan | — |
| Recruiting | Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis NCT04557969 | National Cancer Institute (NCI) | — |
| Completed | A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib NCT04633122 | Zai Lab (Shanghai) Co., Ltd. | Phase 2 |
| Recruiting | A Study of HQP1351 in Patients With GIST or Other Solid Tumors NCT03594422 | Ascentage Pharma Group Inc. | Phase 1 |
| Completed | A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal St NCT03158103 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Sel NCT02574663 | TG Therapeutics, Inc. | Phase 1 |
| Terminated | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors NCT02452424 | Daiichi Sankyo | Phase 1 / Phase 2 |
| Completed | Unifying Advanced Treatment With Advanced Imaging NCT03404076 | Heidelberg University | — |
| Completed | Management of Imatinib-associated Severe Skin Rash in Patients With Gastrointestinal Stromal Tumor NCT03440515 | Asan Medical Center | Phase 2 |
| Unknown | Circulating Cell-free Tumor DNA in the Plasma of Patients With Gastrointestinal Stromal Tumors (GIST) NCT02443948 | Fondazione del Piemonte per l'Oncologia | — |
| Active Not Recruiting | MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumo NCT01991379 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Terminated | A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastroi NCT01316263 | Eli Lilly and Company | Phase 2 |
| Terminated | Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST) NCT01391611 | Kristen Ganjoo | Phase 2 |
| Completed | A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients NCT01294202 | Astex Pharmaceuticals, Inc. | Phase 2 |
| Completed | Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST) NCT00867113 | Novartis Pharmaceuticals | Phase 2 |
| Terminated | Advanced Gastrointestinal Endoscopic Imaging NCT01034670 | Stanford University | N/A |
| Completed | A Study of Nilotinib Versus Imatinib in GIST Patients NCT00785785 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma NCT00780494 | Stanford University | Phase 2 |
| Completed | B-Receptor Signaling in Cardiomyopathy NCT01135849 | Daniel Bernstein | — |
| Terminated | Permission to Collect Blood Over Time for Research NCT00767234 | Stanford University | — |
| Completed | A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen NCT00623831 | Ludwig Institute for Cancer Research | Phase 1 |
| Completed | Trial of Dasatinib in Advanced Sarcomas NCT00464620 | Sarcoma Alliance for Research through Collaboration | Phase 2 |
| Recruiting | Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma NCT01048281 | Stanford University | — |